Abstract:Background: Kidney cancer is a common and deadly disease. Over 90% of all kidney cancers are classified as renal cell carcinoma (RCC), of which clear-cell RCC (ccRCC) is the most predominant subtype. VHL is a tumor suppressor and plays a pivotal role in ccRCC development. While >50% of ccRCC patients present with pathogenic VHL mutations, deep deletions and low VHL expression are also common. Over the past two decades, therapeutic advances have been made for metastatic ccRCC; however, none directly target VHL, and the five-year overall survival for metastatic ccRCC remains ~12%. Here, we used a fusion protein, consisting of a deactivated Cas9 (dCas9) linked to the histone acetyltransferase protein p300, to determine if VHL activation initiates programmed cell death in a preclinical model of ccRCC. Methods: Caki-1 cells are a human ccRCC line, are wild-type VHL with low-moderate expression. Caki-1 cells were stably transduced with our dCas9-p300 system via lentivirus, and then transfected with either sgRNAs targeting VHL or a non-targeting (NT) sgRNA. Ten targeting sgRNAs were designed, with eight starting within -120 bp from the VHL1 transcriptional start site (chr3:10141778), and two starting within +50 bp after the TSS. VHL gene expression changes from baseline were evaluated by RT-qPCR at 8h, 24h and 48h after sgRNA transfection. At 24-72h, Caki-1 cells were harvested and stained with Annexin V and propidium iodide; apoptosis and necrosis were then assessed by flow cytometry. Last, to determine whether VHL reactivation triggered necroptosis, MLKL gene expression changes were evaluated by RT-qPCR at 8h, 24h and 48h. Results: Four targeting sgRNAs met internal thresholds for evaluation within our dCas9-300 system: sgRNA3 bp), sgRNA4, sgRNA9, and sgRNA10. Significant increases in VHL expression were observed at 8h for sgRNA3 and sgRNA10 (62.4% and 56.5%, respectively; both P<0.0001, n=3), at 24h for all four sgRNAs (range 91.1-236.1%; all P<0.0001, n=3), and again at 48h for all four sgRNAs (range 84.4-194.4%; P<0.0001, n=3). At 48h and 72h, sgRNA4 (6.78% and 7.35%) and sgRNA9 (6.71% and 6.76%) showed evidence of necroptosis activation. sgRNA4 demonstrated significantly increased MLKL expression at 24h and 48h (199.6% and 144.6%; both P<0.0001, n=3) as did sgRNA9 (192.7% and 235.6%; both P<0.0001, n=3) suggesting necrosome activation. Conclusions: To our knowledge, this is the first study to associate VHL reactivation with increased MLKL expression and necroptosis initiation. These data support continued development of an experimental system we have pioneered (PMID: 31712774), which will leverage chemical-induced proximity to reactivate VHL. Citation Format: Manfred S. Meng, Ryan M. Kemper, Travis J. Nelson, Nathaniel A. Hathaway, Daniel James Crona. VHL1 activation with a CRISPR-based gene activation platform causes increased MLKL expression and triggers necroptosis in renal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3159.

CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma

Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma

Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma

VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis

VHL mutation drives human clear cell renal cell carcinoma progression through PI3K/AKT-dependent cholesteryl ester accumulation

A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding

High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells

Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways

Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic response

Abstract 3159: VHL1 activation with a CRISPR-based gene activation platform causes increased MLKL expression and triggers necroptosis in renal cell carcinoma

VHLmissense Mutation Delineate Aggressive Clear Cell Renal Cell Carcinoma Subtype with Favorable Immunotherapeutic Response

Identification of Novel VHL Regulated Genes by Transcriptomic Analysis of RCC10 Renal Carcinoma Cells.

VHLSynthetic Lethality Signatures Uncovered by Genotype-specific CRISPR-Cas9 Screens

Multi-Omics Profiling to Assess Signaling Changes upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines

VHL Substrate Transcription Factor ZHX2 As an Oncogenic Driver in Clear Cell Renal Cell Carcinoma

Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma

Abstract PR007: Von Hippel Lindau (VHL) tumor suppressor regulates m6A-dependent gene expression involved in renal tumorigenesis

Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated Ccrcc.

A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model.

VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway